NL-OMON48876招募中2 期
Allogeneic bone marrow derived mesenchymal stromal cells for the treatment of refractory proctitis in Ulcerative Colitis - BMMSC proctitis
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 14
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •a) Men and women >= 18 years of age;
- •b) Patient must have ulcerative colitis confirmed by endoscopic and histologic evidence;
- •c) Inflammation must be limited to the rectum (up to 15 cm beyond the anal verge), confirmed by endoscopy maximum 3 months before baseline (slight inflammation in other parts of the colon is accepted with a maximum Mayo Score of 1);
- •d) Moderate to severe proctitis indicated by a Mayo Score of 2 or 3;
- •e) Proctitis must be refractory to conventional medical therapy. Which means that at some time during the course of the disease, patient must have received rectal 5-ASA therapy and rectal corticosteroid therapy for at least 4 weeks which did not result in an adequate response to treatment;
- •f) If treated with rectal therapy, therapy must be stopped two weeks before endoscopic implantation of MSCs and only restarted after 6 weeks;
- •g) If treated with oral 5-ASA therapy, dose must be stable for 4 weeks prior to study entry and remain on same dose during the first 6 weeks after MSC treatment;
- •h) If treated with oral corticosteroids, dose must be stable for 2 weeks prior to study entry and remain on same dose during the first 6 weeks after MSC treatment;
- •i) If treated with 6-mercaptopurine, methotrexate, azathioprine, vedolizumab or anti-TNF therapy patients must have been on medication for 3 months and a stable dose for 2 months prior to study entry and remain on same dose during the first 6 weeks after MSC treatment;
- •j) If female and of child-bearing age, patient must be non-pregnant, non-breastfeeding, and use adequate contraception;
- •k) Patient is willing to participate in the study and has signed the informed consent.
- •Consent must be obtained prior to any study procedure.
排除标准
- •a) Patients suffering from renal- or hepatic failure;
- •b) Use of any investigational drug within 1 month prior to screening or within 5 half-lives of the investigational agent, whichever is longer;
- •c) Positive stool culture for enteric pathogens (salmonella, shigella, and campylobacter), positive C. difficile toxin, or positive stool ova and parasite exam;
- •d) All active infections requiring treatment;
- •e) Patients who had tuberculosis or an opportunistic infection (e.g., herpes zoster [shingles], cytomegalovirus, Pneumocystis carinii, aspergillosis, histoplasmosis) within 6 months prior to screening;
- •f) Malignancy within the past 5 years (except for squamous or basal cell carcinoma of the skin that has been treated with no evidence of recurrence);
- •g) Any dysplasia in the colon in the past 5 years, except for a successfully removed sporadic adenoma;
- •h) Very severe proctitis; expected to result in hospitalization/ surgery within 3 months;
- •i) Previous treatment with allogeneic MSCs;
- •j) Any other condition which in the opinion of the investigator would make the patient unsuitable for enrollment, or could interfere with the patient participating in and completing the study;
- •k) Patient is unwilling or unable to comply with the study procedures.
研究者
相似试验
进行中（未招募）
1 期
Mesenchymal Stromal Cells for the treatment of Ulcerative Colitislcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2017-003524-75-NLeiden University Medical Center14
尚未招募
不适用
Mesenchymal stromal cell therapy for the treatment of proctitis in ulcerative colitisNL-OMON21802eiden University Medical Center14
已完成
不适用
Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Fistulas in Patients with Refractory Perianal Crohn*s DiseasefistulaM. Crohn10017969NL-OMON36386eids Universitair Medisch Centrum21
进行中（未招募）
不适用
Allogeneic Bone Marrow Derived Mesenchymal Stem Cellsfor the Treatment of Fistulas in Patients withRefractory Perianal Crohn’s Disease - allo bmMSCs CD fistulaEUCTR2009-015680-14-NLeiden University Medical Center
进行中（未招募）
1 期
Safety of bone marrow-derived stem cells in treatment of knee cartilage defects.EUCTR2018-004067-31-CZBioinova, s.r.o.6